Adamas Pharmaceuticals
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Adamas Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).
Adamas Pharmaceuticals: 10 sponsored US clinical trials, none currently recruiting.
Adamas Pharmaceuticals sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 8 completed. 7 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Levodopa Induced Dyskinesia (LID), with 2 trials.
Top-decile sponsor footprint
Adamas Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
8 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
10 total, page 1 of 1
A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
NCT03567057
Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment
NCT03436199
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
NCT02471222
Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
NCT02274766
Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.
NCT02153645
Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID
NCT02153632
Open-Label Safety Study of ADS-5102 in PD Patients With LID
NCT02202551
ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)
NCT02136914
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
NCT01397422
Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects
NCT00979251
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
| Phase 3 | 7 |
Therapeutic Areas
How the Adamas Pharmaceuticals archive is shaped
10 indexed studies, none listed as recruiting (0% open); 8 completed (80%).
Phase mix: 7 late (III/IV) vs 3 early (I/II) (later-stage heavy).
Top condition: Levodopa Induced Dyskinesia (LID) (2 trials), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Adamas Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Adamas Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 10 archived trials
- Adverum Biotechnologies · 10 trials · 30% recruiting
- Aevi Genomic Medicine, LLC, a Cerecor company · 10 trials · 0% recruiting
- Agouron Pharmaceuticals · 10 trials · 0% recruiting
- Aimmune Therapeutics · 10 trials · 10% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Adamas Pharmaceuticals page
10 registered trials is a research-attention snapshot, not an endorsement of Adamas Pharmaceuticals or any single study.
- None of Adamas Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Levodopa Induced Dyskinesia (LID) is the condition Adamas Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Levodopa Induced Dyskinesia (LID) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Adamas Pharmaceuticals pipeline card: 10 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.